Pharmaceutical

EMA recommends expanding approval of Ofev to children and adolescents

Boehringer Ingelheim’s blockbuster Ofev could be set for an expanded indication in children and adolescents with fibrosing ILDs.

Dec 17, 2024 - 06:00
EMA recommends expanding approval of Ofev to children and adolescents
Boehringer Ingelheim’s blockbuster Ofev could be set for an expanded indication in children and adolescents with fibrosing ILDs.
Read the original article

Tags:

Previous Article

Small cell lung cancer: Navigating the global clinical trial landscape

Next Article

Denmark’s HTA evolution

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Organization behind ProMed defends move to subscription-based model

Organization behind ProMed defends move to subscription...

Aug 5, 2023

Panbela Therapeutics and Johns Hopkins to expand ivospemin development

Panbela Therapeutics and Johns Hopkins to expand ivospe...

Apr 4, 2023

Pharmaceutical Wholesalers for the Pharmaceutical Industry

Pharmaceutical Wholesalers for the Pharmaceutical Industry

Sep 24, 2024